艾力斯：甲磺酸伏美替尼片被纳入拟突破性治疗品种公示

Core Viewpoint - The company艾力斯 announced that its core product,甲磺酸伏美替尼片 (brand name "艾弗沙"), has been included in the list of proposed breakthrough therapies by the National Medical Products Administration (NMPA) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR PACC mutations [1] Group 1 - The proposed indication for伏美替尼 is as a first-line treatment for adult patients with locally advanced or metastatic NSCLC [1] - The public announcement period for this proposed breakthrough therapy is from December 25, 2025, to January 4, 2026 [1]